December 5, 2019

TissueTech Receives 2019 Customer Digital Transformation Award

Award celebrates TissueTech for being a true innovator by incorporating the use of digital technology to redefine clinical research and development.

Miami, Fla. – December 4, 2019 – TissueTech, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products marketed through its subsidiaries BioTissue, Inc. and Amniox Medical, Inc., was awarded the 2019 Customer Digital Transformation Award by Medidata on November 13, 2019 at Medidata NEXT NYC, the premier conference dedicated to the digital transformation of life sciences. This award recognizes TissueTech’s successful migration to Medidata’s unified data platform and the resultant effectiveness the company has achieved in addressing the complexity of clinical trials and associated data handling.

Medidata NEXT NYC is the centerpiece of the largest annual event series of its kind, which attracts over 3,000 attendees across seven global events. The annual event brings together life science leaders for two days of forward-thinking conversations, knowledge sharing, and meetings to drive the industry forward with the joint mission of improving patient lives. Medidata is now part of Dassault Systèmes.

“This award acknowledges our effort to more effectively scale operations and innovate at a faster pace than traditional businesses. As a result of migrating to a unified data platform, we can more effectively design, plan, and meet the rigorous demands associated with late-stage clinical trials,” said Amy Tseng, TissueTech President and Chief Executive Officer. “This migration demanded a cross-functional effort between members of clinical operations, regulatory, information technology, and quality departments. I am very proud of what these teams were able to accomplish in less than a year.”

Rapid innovation in the life sciences industry is fueling new drug discoveries and producing large volumes of research data. In fact, a 2018 study by the Tufts Center for the Study of Drug Development found that Phase III studies see an 86 percent increase in the number of data points collected.1  Challenges associated with data management can be considerable in clinical trials, where enormous amounts of data are generated from diverse clinical sites, and then assembled, analyzed, and organized.

“The Medidata Customer Award highlights the most innovative approaches to the digital transformation of life sciences,” said Michael Pray, EVP, Global Sales at Medidata. “We are proud to recognize TissueTech for their clinical advancements and dedication to patients around the world. Congratulations!”

About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., pioneered the development and clinical application of human placental tissue-based products. Founded in 1997, BioTissue markets products for the ophthalmology and optometry markets; and Amniox markets products for use in the musculoskeletal and wound care markets. Clinicians have performed more than 500,000 human implants with the company’s products and published more than 360 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous use for promoting ophthalmic wound healing as acting as an anti-scarring, anti-inflammatory and anti-angiogenic agent and supporting epithelial adhesion and differentiation. Learn more at

Related Content